Content Hub

New Engager Spotlights

Myriad Genetics Engager

Tuesday, February 3, 2026 | 9:30-11:30

Ahead of next week, take an exclusive look at the agenda breakdown of Myriad Genetics' Engager Session. Look forward to participating in interactive discussions revolving around the real-world application of MRD data in patient management, trial design, and therapeutic development.

Hear From:

Lou Welebob, Senior Vice President of Biopharma Companion Diagnostics, Myriad

Dale Muzzey, Chief Scientific Officer, Myriad

Tadayoshi Hashimoto, Physician, National Cancer Center Hospital East, Japan

Hosein Kouros-Mehr, Senior Vice President, R&D, Myriad

Personalis Engager

Tuesday, February 3, 2026 | 12:00-2:30

Download a PDF copy outlining the agenda of Personalis' Engager Session, taking place on Tuesday. Hear directly from industry leaders on the role of MRD in accelerating clinical developments to make meaningful adaptations to your current workflows.

Hear From:

Stephane Mouradian, Senior Vice President, Business Development, Personalis

Jyoti Mayadev, Professor & Vice Chair, Developmental Therapeutics, University of California, San Diego

Deepshikha Bhandari, Senior Vice President - Quality, Regulatory & Clinical Compliance, Personalis

Zoe Assaf, Senior Director, Cancer Genomics & Emerging Technologies, Revolution Medicines

Lauren Leiman, Executive Director, BLOODPAC

Natera Engager

Tuesday, February 3, 2026 | 3:00-5:30

Access a preview of the agenda set to take place at Natera's Engager Session. In your copy, find the complete details on the experts sharing data from Foresight’s phased-variant technology, that has been recently integrated into their Signatera™ platform.

Hear From:

Sandra Close, Chief Operating Officer, Foresight, now part of Natera

Jeffrey Gregg, Vice President, Medical Affairs, Foresight, now part of Natera

Dejan Knezevic, PhD, Senior Director, Biopharma Partnerships, Natera

Eser Kirkizlar, Senior Director, Bioinformatics, Natera

Guardant Engager

Tuesday, February 3, 2026 | 6:00-8:30

Get prepared for the 10th Liquid Biopsy for Precision Oncology Summit by accessing your copy of the program for Guardant Health's Engager Session. Inside find out how biopharma researchers and clinical oncologists are using novel biomarkers to bring more effective therapies to patients in need.

Hear From:

Steffan Ho M.D., Vice President & Head, Translational Oncology, Pfizer

Zoe June Assaf, Senior Director, Cancer Genomics & Emerging Technologies, Revolution Medicines

Justin Odegaard, Senior Vice President, Product Management, Guardant Health

Jean-Francois Martini, Sr Director, Translational strategy, Guardant Health

Ben Herzberg, Assistant Professor, Medicine, Columbia University Irving Medical Center

Foundation Medicine Engager

Wednesday, February 4, 2026 | 7:05-9:10

Sneak a peek at the discussions, experts and perspectives you can expect at Foundation Medicine's Engager Session. Gain an exclusive look at the next generation biomarkers driving smarter clinical trial enrolment and monitoring.

Hear From:

Jason Adams, Vice President & Head, Biopharma Business Development, Foundation Medicine

Brennan Decker, Senior Pathologist, Associate Medical Director & Director, Clinical Biomarkers, Foundation Medicine

Steffan Ho, Vice President & Head, Translational Oncology, Pfizer

David Weingeist, Director, Scientific & Oncology Diagnostics Leader, Johnson & Johnson

Fernando Cruz-Guilloty, Director, Oncology Precision Medicine & Lung Franchise Lead, Johnson & Johnson